|
Originally published In Press as doi:10.1074/jbc.M204793200 on October 9, 2002
J. Biol. Chem., Vol. 277, Issue 51, 49799-49807, December 20, 2002
Anti-semaphorin 3A Antibodies Rescue Retinal Ganglion
Cells from Cell Death following Optic Nerve Axotomy*
Anat
Shirvan §,
Michal
Kimron¶,
Vered
Holdengreber ,
Ilan
Ziv ,
Yehuda
Ben-Shaul ,
Shlomo
Melamed**,
Eldad
Melamed ,
Ari
Barzilai¶ , and
Arieh S.
Solomon**
From the Department of Neurology and the Felsenstein
Medical Research Center, Rabin Medical Center, Beilinson Campus, and
the Sackler School of Medicine, Petach Tiqva 49100 and the
¶ Department of Neurobiochemistry, George S. Wise Faculty of Life
Sciences, the Department of Cell Research and Immunology, and
the ** Sam Rothberg Glaucoma Center, Goldschleger Eye
Research Institute, Tel Aviv University, Ramat Aviv,
Tel Aviv 69978, Israel
Received for publication, May 16, 2002, and in revised form, September 18, 2002
 |
ABSTRACT |
Damage to the optic nerve in mammals induces
retrograde degeneration and apoptosis of the retinal ganglion cell
(RGC) bodies. The mechanisms that mediate the response of the neuronal
cells to the axonal injury are still unknown. We have previously
shown that semaphorins, axon guidance molecules with repulsive
cues, are capable of mediating apoptosis in cultured neuronal cells (Shirvan, A., Ziv, I., Fleminger, G., Shina, R., He, Z., Brudo, I.,
Melamed, E., and Brazilai, A. (1999) J. Neurochem. 73, 961-971). In this study, we examined the involvement of semaphorins in
an in vivo experimental animal model of complete axotomy of
the rat optic nerve. We demonstrate that a marked induction of type III semaphorin proteins takes place in ipsilateral retinas at early stages
following axotomy, well before any morphological signs of RGC apoptosis
can be detected. Time course analysis revealed that a peak of
expression occurred after 2-3 days and then declined. A small
conserved peptide derived from semaphorin 3A that was previously shown
to induce neuronal death in culture was capable of inducing RGC loss
upon its intravitreous injection into the rat eye. Moreover, we
demonstrate a marked inhibition of RGC loss when axotomized eyes were
co-treated by intravitreous injection of function-blocking antibodies
against the semaphorin 3A-derived peptide. Marked neuronal protection
from degeneration was also observed when the antibodies were applied
24 h post-injury. We therefore suggest that semaphorins are key
proteins that modulate the cell fate of axotomized RGC. Neutralization
of the semaphorin repulsive function may serve as a promising new
approach for treatment of traumatic injury in the adult mammalian
central nervous system or of ophthalmologic diseases such as glaucoma
and ischemic optic neuropathy that induce apoptotic RGC death.
 |
INTRODUCTION |
Axon guidance molecules are a large family of secreted and
membrane-bound proteins that participate in axonal pathway formation during development of the nervous system in a receptor-mediated process
(reviewed in Refs. 1-4). In particular, several members of the
semaphorin family of proteins may play an important role in navigating
axonal networks throughout neuronal development via their
chemorepulsive activity on neuronal growth cones (5-7). The basic
structure of sema includes a semaphorin domain of 500 bp as well
as immunoglobulin-like and thrombospondin domains. Semaphorins are
currently grouped into nine subclasses, which contain both secreted and
transmembranous members (3, 8). Inhibition of axonal outgrowth was
demonstrated by some semaphorins; it occurs at the tip of the growth
cone and is manifested by depolymerization and loss of F-actin (9, 10).
The downstream pathways by which semaphorins exert their actions are
still unclear, but are known to include the neuropilin and plexin
receptors (11, 12) as well as intracellular CRMP-62
(collapsin response mediator
protein) (13) and G-proteins (14). Interestingly, it has
recently been shown that semaphorins are bifunctional molecules, and
cyclic nucleotides can regulate their activity from repulsion to
attraction (15, 16). Involvement of semaphorin family members in other physiological phenomena was suggested, such as regulation of organ formation outside the nervous system (17), regulation of the immune
response (18, 19), and tumor-related cell survival mechanisms (20,
21).
We have recently shown a functional involvement of semaphorins in
neuronal apoptosis (22). In a model system of cultured chick
sympathetic neurons undergoing dopamine-induced apoptosis, induction of
both collapsin-1, now termed chick semaphorin 3A (Sema3A1; a secreted and
diffusible type III semaphorin with repulsive activity), and CRMP-62
was detected. This up-regulation was evident at the early stages
following exposure to the apoptotic trigger, even before the emergence
of the typical morphological signs of apoptosis. The up-regulation of
Sema3A expression was coupled to the onset of the commitment time point
of the neurons to the death process. Moreover, marked and prolonged
protection of neurons from dopamine-induced apoptosis was achieved by
co-treatment of cells with function-blocking anti-Sema3A antibodies.
Antibodies against neuropilin-1, the putative semaphorin III/Sema3A
receptor (23, 24), also inhibited neuronal apoptosis. In addition, induction of apoptosis was evident by treatment of neurons with a
recombinant human semaphorin III protein (22). These results demonstrated a correlation between the semaphorin death-inducing activity and the repulsive activity on axonal growth cones. We therefore proposed that repulsive diffusible cues, acting on
appropriate receptor-bearing cells, could modulate neuronal cell fate
(22). Further support for our studies was provided by the indication of
involvement of semaphorins in apoptosis of sensory neurons (25) and
neuronal progenitor cells (26).
The molecular mechanisms responsible for transforming the repellent
guidance cue from the damaged axon into a death signal that may affect
the cell body are unknown. Therefore, it was important to further
substantiate and extend our in vitro findings to an experimental in vivo model of neuronal apoptosis. One of the
models used to study the fate of injured neurons in the adult central nervous system is the visual system, in which retinal apoptosis occurs
following axonal injury to the optic nerve. In rats, transection of the
optic nerve close to the cell bodies is a trigger for retrograde degeneration and delayed death of retinal ganglion cells (RGC) (27).
The mechanism that initiates the loss of retinal cell bodies as a
function of axonal injury is still unknown, and several hypotheses have
been suggested (reviewed in Ref. 28). However, many lines of evidence
indicate that apoptotic processes are responsible for the loss of RGC
in the retina following axotomy of the optic nerve and for the loss of
other axotomized or traumatized central nervous system neurons (27,
29-31). This secondary death of the RGC also serves as an example of
the correlation between neuronal cell survival and axonal integrity.
Such a correlation is supported by studies indicating that when an axon
is injured, the cell body goes through a series of changes that may
culminate in the death of the axotomized neurons (32).
Following optic nerve axotomy in adult rats, initial reduction of the
original population of RGC is observed 5-7 days after injury. A rapid
process of cell death then takes place, and >80% of the RGC die
within 2 weeks after the injury (27, 33-35). Because a relatively long
interval precedes this massive death process, it can be speculated that
a time window exists in which protective intervention with modulators
that attenuate or prevent cell death can be employed. Indeed, partial
and temporal rescue of RGC from axotomy-induced apoptosis was obtained
by several approaches. These included early treatment with microglial
inhibitors (36, 37), glial or brain-derived neurotrophic factors (38,
39), caspase inhibitors (40, 41), implantation of stimulated
macrophages (42), and overexpression of Bcl-2 (43, 44).
Therefore, we chose the visual system as an in vivo model in
which neuronal apoptosis can be induced and, more importantly, that can
also offer an opportunity to intervene and alter the fate of the
injured RGC.
We now report that high levels of semaphorin expression are transiently
induced in the rat retina at an early post-axotomy stage and before any
RGC death is observed. Furthermore, we demonstrate that rescue of RGC
from axotomy-induced degeneration can be achieved by treatment of the
injured retina with intraocular administration of anti-Sema3A
function-blocking antibodies.
 |
MATERIALS AND METHODS |
Optic Nerve Transection in the Rat
Adult male Sprague-Dawley rats (8-10 weeks old, 300 g) were deeply anesthetized (50 mg/kg xylazine and 35 mg/kg ketamine), and their left optic nerves were exposed by lateral canthotomy. The
conjuctivae were incised lateral to the cornea, and the retractor bulbus muscles were separated. Through a small opening in the menings (~200 µm), the nerve fibers were completely
transected at a distance of 2-3 mm from the globe. The procedure was
performed without damage to the nerve vasculature and optic nerve blood supply and with minimal damage to the meninges by the use of a specially designed glass dissector with a 200-µm tip and a smooth blunt edge (45). The injury was unilateral in all animals, and the
other eye served as a control.
Retrograde Labeling of RGC
At day 8 following axotomy of the optic nerve, the rats were
deeply anesthetized. Small crystals of the lipophilic neurotracer dye
4-(4-(didecylamino)styryl)-N-methylpyridinium iodide
(4-Di-10-Asp; Molecular Probes, Inc.) were dissolved gently in
incomplete Freund's adjuvant (at a concentration of 1 mM;
Difco). This dye serves as a marker for living RGC because it is
transmitted through the axonal network and stains the cell bodies of
live neurons only, whereas nonviable neurons as well as other cell
types such as endothelial cells remained unstained (42). The dye was
applied to the transected nerve 0.5 mm from the proximal border of the transection site. The site of injury was visible by its grayish color
in comparison with the rest of the nerve, which maintained its original
color. Four days after dye application, retinas were excised,
whole-mounted on Millipore filters, fixed in 4% paraformaldehyde in
phosphate-buffered saline (PBS), and viewed under a fluorescent microscope using a fluorescein isothiocyanate filter.
Evaluation of RGC Survival
Two independent and blinded researchers counted the number of
labeled RGC in flat-mounted retinas by fluorescent microscopy. For each
retina, 20 representative microscopic fields were evaluated: 10 fields
from the peripheral area and 10 fields from the central area (each
field covering an area of 0.069 mm2). Central retinal areas
were defined as located within two-thirds from the optic disc,
and peripheral retinal areas were defined as located within one-third
of the retinal radius. (These definitions were based on the apparent
change in density of RGC between the two central and peripheral areas.)
For comparison, we performed a previously described counting method
(35) that divides each quadrant of the retina into three different
areas and counts a total of two microscopic fields from each area of
the retina (making a total of 12 fields). However, when the two
counting protocols were compared (by counting the RGC in control
retinas), we found that the numbers came out the same. Therefore, we
saw no advantage in using the previously described method, and we used
the above protocol for the entire analysis. Retinas from eyes that were subjected to axotomy contained less RGC and were compared with intact retinas.
Data Analysis
Histological parameters are presented as means ± S.E.
Mann-Whitney and analysis of variance tests were used to assess the results.
Treatment with Sema3A-derived Peptides
Sema3A-derived peptides (Pep1A, corresponding to amino acids
363-380 from chick Sema3A, and the control peptide Pep3A,
corresponding to amino acids 240-256 according to Ref. 46) were
synthesized by Genemed Biotechnologies, Inc. (San Francisco, CA) and
purified to homogeneity on a RP-18 column (Vydac, Hesperia, CA)
using a Gilson Model 303 HPLC system. Prior to injection, each peptide was dissolved in PBS, and a total amount of 0.33 mg/kg in a volume of 2 µl was injected into the vitreous body of one eye, and the opposite
eye served as a control. Insertion was at the corneal limbal
border behind the lens, over the optic nerve head area and close to the
retinal surface.
Antibody Preparation
Polyclonal Anti-Sema3A Antibodies--
Polyclonal anti-Sema3A
antibodies were prepared in rabbits by immunization against Pep1A, a
peptide corresponding to amino acids 363-380 from chick Sema3A (46).
The sequence of this peptide is identical in chick Sema3A, human
semaphorin III, and rat and mouse semaphorin D. These antibodies were
therefore expected to react with the highly conserved Sema3A/semaphorin
III/semaphorin D proteins present in those species. Synthetic peptides
were obtained and purified as described above. Peptide conjugates with
keyhole limpet hemocyanin (KLH; Sigma) were prepared by incubation of the peptide (3 mg) with 1 ml of KLH containing 10 mg of protein and
1.25% glutaraldehyde. After 3-4 min at room temperature, the reaction
was stopped by addition of 0.1 ml of 1 M glycine in water. Two rabbits were immunized against the peptide. Rabbits were immunized by subcutaneous injections of 0.1 mg of KLH-conjugated peptide. Booster
shots were injected 2, 5, and 8 weeks after immunization. The titer of
the antibodies in the serum was 1:104 as determined by
enzyme-linked immunosorbent assay and compared with preimmune serum.
Both the immune and preimmune sera were fractionated using 40%
saturated ammonium sulfate and dialyzed against PBS. These antibodies
were previously characterized and shown to react with the chick Sema3A
protein and to act as function-blocking antibodies that block the
repellent activity of human semaphorin III (22). These antibodies were
used in this study for inhibiting the effect of axotomy.
Monoclonal Anti-semaphorin Antibodies--
Balb/c mice
were immunized subcutaneously with 50 µg of KLH-conjugated Pep1A in
complete Freund's adjuvant and boosted four times subcutaneously with
50 µg of KLH-conjugated Pep1A in incomplete Freund's adjuvant at
3-week intervals. Three days before fusion, mice were boosted by
intravenously injection of 50 µg of KLH-conjugated Pep1A in PBS. One
mouse that had a relatively high titer (as evidenced by enzyme-linked
immunosorbent assay with bovine serum albumin-conjugated Pep1A) and
that was also positive in Western blot analysis, immunohistochemistry, and immunoprecipitation was chosen for fusion. Hybridomas were prepared
by fusion of spleen cells with mouse myeloma NS0 cells (donated
by Dr. C. Milstein. Following the cloning procedure, positive clones
were chosen for the preparation of ascitic fluids, which was carried
out by intraperitoneal injection of 2-5 × 106
hybridoma cells into pristane-primed male mice. The fluid was harvested starting at 7-10 days and then twice every 2nd day. Ascitic
fluids were centrifuged at 800 × g and kept frozen at 80 °C. The antibodies were characterized by their ability to react
with a single protein with the right molecular mass (110 kDa) in chick
embryo retinas at embryonic day 18, by their ability to
immunoprecipitate this protein, and by their ability to label the
ganglion cell layer of embryonic day 18 retinal slices. These antibodies were used in this study for both immunohistochemistry and
Western blot analysis.
Protective Antibody Treatment
For protective antibody treatment, the axotomized animals were
grouped into four groups of four to six rats each. Two groups were
injected with the partially purified polyclonal anti-Sema3A antibody
(at a single dose of 30 µg in a volume of 2 µl). One of the groups
was injected immediately after optic nerve transection (time 0),
and the second group was injected with the antibody 24 h
post-injury. The other two groups served as controls: one group was
injected with preimmune serum (30 µg in a volume of 2 µl, taken
from the same rabbit used for immunization), and the second with PBS.
The anti-Sema3A antibody was injected into the vitreous body of the
axotomized eye. Injection was performed using a glass pipette that was
inserted into the eye globe. Insertion was at the corneal limbic border
behind the lens, over the optic nerve head area and close to the
retinal surface. Injection of the anti-Sema3A antibody did not cause
any signs of inflammation or irritation or any other changes that may
indicate that this treatment is toxic. Clinical examination of the eyes
was performed using a slit lamp, and the eyes were monitored for any
signs of hyperemia, edema, discharge, fibrin, and other inflammatory parameters.
Western Blot Analysis
Western blot analysis was performed as described by Harlow and
Lane (65) using 8% polyacrylamide gels. Each lane was loaded with an
equal amount of protein extracts (175 µg), which, following electrophoresis, were transferred to an Immobilon (polyvinylidene disulfide) membrane for 1.5 h. Blots were stained with Ponceau to
verify equal loading and transfer of proteins. Membranes were then
probed with monoclonal anti-semaphorin antibodies (1:1000 dilution).
The intensity of the signal was determined using the ECL-Plus detection
system (Amersham Biosciences, Buckinghamshire, UK).
Immunohistochemistry
Tissue Preparation--
Dissected retinas from optic
nerve-axotomized rat eyes and from non-injured control were
from optic nerve-axotomized rat eyes, and controls were fixed in 3.5%
paraformaldehyde in PBS for 1-2 h and then infiltrated for
cryoprotection with 4% sucrose for 2 h at 4 °C, followed by
20% sucrose + 5% glycerol in PBS at the same temperature, overnight.
Fixed tissue was quickly frozen in liquid nitrogen. Cross-sections (10 µm) were placed on subbed slides (1% gelatin containing 0.3%
chromium potassium sulfate) and stored at 20 °C.
Labeling--
Sections were washed with PBS and incubated in PBS
and 1% bovine serum albumin for 30 min at room temperature. The
sections were incubated overnight with the primary monoclonal antibody against Sema3A at 4 °C. The slides were then washed three times with
PBS and incubated with fluorescein isothiocyanate-conjugated goat anti-rabbit IgG for 1 h at room temperature. After washing three times with PBS, the sections were mounted with galvanol. Observations were made and photography was carried out with a Zeiss
Axioplan microscope with an appropriate filter. As a control, the
sections were reacted either with preimmune rabbit serum or with the
secondary antibody only.
Hoechst Staining
Cross-sections were stained with a cell-permeable form of
bisbenzimide (Hoechst 33342) at a concentration of 4 µg/ml for 30 min
at 37 °C. Cells were visualized by UV light microscopy, and the
relative number of apoptotic nuclei with condensed or fragmented chromatin was then evaluated and compared with non-apoptotic nuclei, showing a pale and diffuse staining. Photomicrographs using a UV filter
were taken for documentation.
 |
RESULTS |
Experimental Model of Complete Axotomy of the Rat Optic
Nerve--
In the adult rat, injury to the optic nerve leads to
delayed apoptotic death of the RGC. To establish the experimental
model, rats were subjected to intrameningeal complete axotomy of the optic nerve in one eye, whereas the second eye served as a control. To
demonstrate the effect of axotomy on RGC in this experimental system,
two approaches were used. One method estimated the number of live RGC
that were still detected 12 days following the injury. The RGC from one
eye that was subjected to optic nerve axotomy were retrograde-labeled
by application (at day 8) of the neurotracer dye 4-Di-10-Asp, and the
retina was fixed and flat-mounted 4 days later. Non-axotomized eyes
taken from different normal rats (that were not subjected to optic
nerve axotomy) served as controls. The retinas were then observed under
a fluorescence microscope (Fig. 1). The
axotomized retinas appeared to be depleted, with very few live RGC
compared with intact retinas, in which multiple cells were observed,
and the large RGC exhibited long neuritic processes. The number of
stained (live) RGC was counted, and the results are presented in
Table I. At 12 days after
the injury (8 days after axotomy + 4 days of staining), a massive loss
of RGC was observed in both the central and peripheral retinal areas. The survival rates were 35 and 52%, respectively. The higher death rate of the central RGC may be explained by the proximity to the injury
site, which was close to the cell bodies of these neurons. The overall
RGC death in our experimental system was compatible with results from
previously published protocols following 8 days of axotomy (35) and was
~60%.

View larger version (108K):
[in this window]
[in a new window]
|
Fig. 1.
Loss of RGC following optic nerve
injury. Rats (n = 4) were axotomized in one eye;
and 12 days later, the remaining RGC were retrograde-labeled for 4 days
with the neurotracer 4-Di-10-Asp. Non-axotomized rats
(n = 4) served as controls. The photomicrographs
exhibit whole-mounted retinas stained with the neurotracer 4-Di-10-Asp
and were taken from intact (A) and axotomized (B)
eyes. Note the difference in RGC densities. The two photomicrographs
were taken of the peripheral retinal area under identical conditions,
and the difference in contrast between A and B
stems from the higher fluorescence of the live RGC in A. Bar = 25 µm.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Effect of anti-Sema3A antibody on RGC survival following axotomy
Shown are RGC numbers 8 days after optic nerve axotomy either with no
treatment or with intraocular injection of preimmune serum (immediately
following injury) or anti-Sema3A antibodies. The numbers in the
Survival columns show percentage of change in the number of
RGC/treatment. All values (central and peripheral areas and average)
were tested for statistical significance using the Mann-Whitney
non-parametric test. RGC numbers differed significantly between control
and axotomized and between axotomized versus
antibody-treated injured eyes (see also Fig.
6C).
|
|
The second method evaluated whether apoptotic cells can be detected in
retinal cross-sections following 12 days of axotomy. For this purpose,
retinal sections were stained with Hoechst 33342, after which the RGC
were examined for the presence of chromatin changes. The relative
number of cells in the axotomized eye with condensed or fragmented
chromatin, indicating apoptosis, was evaluated and compared with that
in control retinas of non-axotomized eyes, which showed only a pale and
diffuse staining. Fig. 2 shows that, as a
result of axotomy, there was a massive loss of the ganglion cells in
the injured eye compared with the non-injured eye. Twelve days
after the damage, the estimated density of ganglion
cells/mm2 in this layer was dramatically decreased.
Moreover, a significant number of apoptotic cells could be identified
using the Hoechst nuclear staining method (Fig. 2), which identifies
pyknotic nuclei and chromatin fragmentation as hallmarks of apoptosis.
In comparison, no apoptotic nuclei could be detected in the
non-axotomized eye. Although the number of nuclei showing apoptotic
morphology in these retinas is small, it is consistent with previous
estimates that cells undergoing death in vivo are eliminated
from the tissue within 3 h or less (47).

View larger version (79K):
[in this window]
[in a new window]
|
Fig. 2.
Rat optic nerve axotomy is associated with
apoptosis and loss of RGC. Rats were axotomized
unilaterally; and 12 days later, the retinas from the injured eyes and
from the control non-injured eyes were removed and fixed.
Cross-sections were prepared, and Hoechst staining was
performed in the retinas from both eyes. A, low
magnification of a retinal slice showing the morphology of a control
non-axotomized retina. The white rectangle points to the
ganglion cell layer. B and C, higher
magnification of retinal slices of control non-axotomized retinas
focusing on the ganglion cell layer. D-H,
enlargement of apoptotic RGC characterized by typical condensed and
fragmented chromatin staining. Moreover, a marked decrease in the
density of RGC compared with control non-axotomized retinas was
observed in the injured retinas. Apoptotic nuclei (condensed and
fragmented) could be detected in the axotomized eye and are marked by
arrows. Bars = 25 µm for
A-C and 10 µm for D-H. GCL,
ganglion cell layer; IPL, inner plexiform layer;
OPL, outer plexiform layer; INL, inner nuclear
layer; PR, photoreceptors.
|
|
Induction of Semaphorin Expression in the Retina following Axotomy
of the Optic Nerve--
To examine whether secreted semaphorins
participate in the degeneration process of RGC, we followed the retinal
expression pattern of semaphorins in the above model system of optic
nerve axotomy. Following axotomy in one eye, the retinas from both eyes were removed at different time intervals and used for
immunohistochemical analysis with the anti-Sema3A antibody. As
controls, we used retinas from the non-axotomized eyes of the same rats
as well as retinas from eyes of different rats that were not subjected
to axotomy. Four to six rats were analyzed at each time point.
Temporal analysis of semaphorin expression as a function of advancement
of the death process was performed. Retinas at 1-4, 10, 12, and 16 days following axotomy were analyzed, and data from several time points
are presented in Fig. 3. Axotomy
initiated a gradual increase in semaphorin expression, starting 24 h post-injury and peaking at 48-72 h. At 96 h, staining declined,
indicating decreased expression. No additional wave of semaphorin
expression could be detected at days 10, 12, and 16, at which time the
RGC death process was fully manifested (data not shown).

View larger version (138K):
[in this window]
[in a new window]
|
Fig. 3.
Time course of semaphorin up-regulation in
the rat retina following optic nerve axotomy. A,
retinas from axotomized eyes were dissected at different intervals (0 (control (C)), 24, 48, 72, and 96 h) after lesion, and
histological frozen sections were subjected to immunohistochemistry.
The retinas were reacted with the monoclonal anti-semaphorin antibody
(1:1000 dilution). Strong staining was evident in the RGC layer and the
inner nuclear layer only in axotomized eyes. A peak of semaphorin
induction was evident after 72 h and then declined. B,
shown is a higher magnification of a control retina (left
panel) and an axotomized retina at 72 h post-axotomy
(right panel). Photomicrographs were taken using a
fluorescein isothiocyanate filter. GCL, ganglion cell layer;
IPL, inner plexiform layer; INL, inner nuclear
layer; OPL, outer plexiform layer; PR,
photoreceptors. Bars = 50 µm.
|
|
The up-regulation of semaphorins reflects induction of their expression
in the RGC layer and the inner nuclear layer, where the amacrine and
bipolar cells reside. Some label was also detected in the outer nuclear
layer, where the horizontal cells are found. It is possible that the
induction of semaphorin expression is transmitted through a
transsynaptic pathway, which may explain why the labeling of
semaphorins could be detected in cell structures of neural origin.
Western blot analysis of retinas prepared at different time points
revealed two specific bands that reacted with the
anti-semaphorin antibodies and showed elevated levels following
axotomy (Fig. 4). One protein has
a molecular mass of 110 kDa and corresponds to the full-length
semaphorin protein (46). A lower molecular mass protein of 36 kDa
appeared to be up-regulated and may represent cleavage of a degradation
product of the full-length protein. Furthermore, at 72 h
post-axotomy, another protein band of 38 kDa could be detected, which
appeared only at this time point; and its relation to the other two
bands has yet to be investigated. Quantitative analysis of the results
showed that, whereas the higher band peaked at 48 h post-injury,
the lower band reached its peak at 72 h. The level of the 110-kDa
protein was elevated 2.3-fold 24 h after the injury and 4-fold
after 48 h and fell to 1.8-fold after 96 h. The 36-kDa
protein was elevated 4.2-fold 72 h after axotomy and fell to
2.5-fold after 96 h. The kinetics of up-regulation of both bands
(in particular, lag time of appearance of the 36-kDa protein) and the
fact that both bands showed a similar level of up-regulation
support the assumption that the two bands are related and that the
small band indeed represents a cleavage product of the large band.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 4.
Up-regulation of semaphorin extracted from
the rat retina following axotomy. A, retinas from
axotomized eyes were dissected at different intervals (0 (control
(C)), 24, 48, 72, and 96 h) after lesion, and total
retinal proteins were extracted, separated on 12.5% polyacrylamide
gel, and blotted onto polyvinylidene disulfide membrane. The membrane
was stained with Ponceau, after which the blot was reacted with the
monoclonal anti-semaphorin antibody (1:1000 dilution). The secondary
antibody was horseradish peroxidase-conjugated goat anti-mouse
IgG (1:25,000 dilution). The blots were developed using the ECL
system. To verify that equal amounts of protein were transferred, the
blots were stripped and reacted with the mouse monoclonal anti-tubulin
antibody (1:25,000 dilution). The secondary antibody was horseradish
peroxidase-conjugated goat anti-mouse IgG (1:25,000 dilution).
B, quantitative analysis of bands was performed using TINA
software, and data are normalized to the corresponding tubulin. The
results are represented as percent of control untreated animals. Three
retinas isolated from three different animals were used per time
point.
|
|
These results indicate that the up-regulation of semaphorins in the
retina peaks shortly after induction of damage, at a time point that
precedes the manifestation of the actual death process of the RGC. High
expression of semaphorins in neurons following nerve injury could have
a potentially inhibitory effect on the outgrowth of nerve sprouts,
thereby preventing regeneration processes.
The Sema3A-derived Peptide Is Capable of Inducing RGC
Loss--
Our previous studies indicate that exposure of neuronal
cells to the full-length Sema3A protein can induce apoptotic death in
cultured neurons, and a similar process was observed when neurons were
exposed to a small conserved peptide derived from Sema3A (Pep1A)
(48). The apoptotic process, accompanied by shrinkage of the
axonal network was observed in both cases, suggesting that Pep1A can
mimic the death-inducing activity of the full-length protein (48).
Based on the evidence of involvement of semaphorins in RGC loss
following axotomy, it was of interest to test whether direct
application of the semaphorin-derived peptide to healthy animals has an
effect on survival of RGC. As a control, a different Sema3A-derived
peptide (Pep3A) was applied to retinas of healthy rats. Pep3A was
previously shown to be nontoxic in neuronal cultures (48) and therefore
was tested as a control peptide. Injection of Pep1A into healthy eyes
resulted in 57% neuronal loss compared with only 9% RGC death in
Pep3A-treated rats, indicating that the death-inducing activity is
specific to Pep1A (Fig. 5). These results
suggest that Pep1A has toxic effects when applied both in
vitro (48) and in vivo and may imply that the exposure
of RGC to secreted Sema3A can propagate the death process within neighboring RGC.

View larger version (60K):
[in this window]
[in a new window]
|
Fig. 5.
Intraretinal injection of Sema3A-derived
peptide Pep1A leads to RGC loss. Both peptides Pep1A and Pep3A
were injected at a concentration of 0.33 mg/kg; and 8 days later,
survival of the RGC was monitored following the application of the
neurotracer dye as described under "Materials and Methods."
A, whole-mounted retinas showing 4-Di-10-Asp-labeled
RGC cells that were exposed to PBS, Pep1A, and Pep3A. Excessive RGC
loss was evident when Pep1A (but not Pep3A) was applied.
Bar = 25 µm. B, quantitative analysis of
Pep1A- and Pep3A-treated RGC. Results are presented as means ± S.E. of live cells/mm2. Statistical analyses were performed
with the Mann-Whitney non-parametric test. ***, p < 0.01.
|
|
Rescue of RGC from Axotomy-induced Degeneration by Anti-Sema3A
Antibodies--
To examine whether the function-blocking antibodies
raised against Sema3A are capable of attenuating the axotomy-induced
degeneration of RGC in the rat model, antibodies were injected into the
axotomized eyes, and RGC viability was monitored. We chose
intravitreous injections because, in this closed system, injected
compounds remain in the vitreous body for a long period (49). Moreover, the close proximity of the vitreous body to the cell bodies of the RGC
layer facilitates the delivery of molecules to their destined targets.
Indeed, intravitreous injection has been successfully used in multiple
studies as an effective mode of administration of compounds to the
retina (50-55). Such administration was also suggested as a
pharmacological tool for treatment of the retina (51, 52).
For the neuroprotection experiments, rats that were axotomized in one
eye were divided randomly into four treatment groups (four to six
animals/group). In the first group, immediately after conducting the
axotomy, PBS solution was administered to the vitreous body of the
damaged eye. In the second group, 30 µg of the IgG fraction from
preimmune serum (originating from the same rabbit used for preparation
of anti-Sema3A antibodies) was injected into the vitreous body of the
damaged eye. In the third group, an IgG fraction from anti-Sema3A
antibodies at a single dose of 30 µg (0.1 mg/kg) was administered. In
the fourth group, identical quantities of anti-Sema3A antibodies were
injected 24 h post-axotomy. Eight days later, the RGC were
retrograde-labeled with the neurotracer dye 4-Di-10-Asp (which is
specifically stains live neurons). The retinas were removed 4 days
following the staining (12 days post-injury), and the number of stained
neurons was counted. In addition, retinas from untreated animals served
as a reference for evaluating the protection level achieved by the
different treatments. The retinas were analyzed by fluorescence
microscopy, and the results are presented in Fig.
6 (A-C). A massive loss of
RGC was observed in retinas from axotomized eyes treated with PBS, and
these retinas appeared to be very depleted. Similar retinal RGC
depletion was obtained when the injured eyes were injected with
preimmune serum (data not shown). However, remarkably higher RGC
densities comparable to those in axotomized retinas were displayed in
retinas treated with anti-Sema3A antibodies (Fig. 6A).
Furthermore, the surviving large neuronal cells appeared to have long
processes of axons, indicating that the axonal network remained intact
(Fig. 6B). For quantitative analysis of the results, we
evaluated the distribution of the surviving retinal neurons. The number
of live (stained) RGC in each experimental group was further estimated
by counting the RGC in the central and peripheral retinal areas (for
specific location of the central and peripheral areas, see "Materials
and Methods"). The results are shown in Fig. 6C and Table
I. In untreated animals, ~65% (central area) and 50% (peripheral
area) of the RGC population had degenerated 8 days following optic
nerve axotomy (comparable to the results obtained by Isenman et
al. (35)). However, treatment of the axotomized retinas with
anti-Sema3A antibodies either at the time of axotomy (designated time
0) or 24 h later resulted in full protection, and retinas were
indistinguishable from those of the control animals (Fig. 6C
and Table I). Treatment of retinas at time 0 with preimmune serum had
no protective effect (Fig. 6, A and C). The RGC
from the central retinal areas compared with the peripheral areas were
more sensitive to the apoptotic trigger, showing lower survival rates,
and were also less responsive to the antibody treatment. Overall, these
results indicate that treatment of axotomized eyes with the anti-Sema3A
antibody leads to a marked increase in the number of surviving RGC in
the central as well as peripheral areas of the retina, which, with no
other treatment, would otherwise suffer a massive loss of RGC. These findings further substantiate the concept that axon guidance molecules with repulsive cues play a role in degeneration of RGC in response to
axotomy. The ability for neuroprotection at time points of up to
24 h following the injury indicates the existence of a therapeutic time window during which RGC death is still reversible and can be
modulated.

View larger version (64K):
[in this window]
[in a new window]
|
Fig. 6.
Rescue of RGC from axotomy-induced
degeneration by the anti-Sema3A antibody. A,
whole-mounted retinas in which the ganglion cells were
retrograde-labeled with the neurotracer dye 4-Di-10-Asp. Representative
micrographs from the corresponding central and peripheral retinal areas
are shown 12 days following axotomy. An axotomized eye subjected to
intravitreous antibody injection and an eye injected with either PBS or
preimmune serum are presented for comparison. Note the higher density
of RGC in the retinas treated with the antibody. Bar = 50 µm. B, higher magnification of axotomized and
anti-Sema3A antibody (anti-sema Ab)-injected retinas. Note
the longer neurite extensions of the large RGC in the anti-Sema3A
antibody-treated retina. Bar = 10 µm. C,
quantitative analysis of the number of RGC in control and axotomized
retinas that were subjected to four different treatments: PBS,
preimmune serum, anti-Sema3A antibody, and 24-h delayed anti-Sema3A
antibody. For each treatment, 10 microscopic fields from central
retinal areas and 10 fields from peripheral retinal areas were
screened. Results are presented as means ± S.E. of live
cells/mm2. 0 and 24 represent
experiments in which the animals underwent axotomy; and immediately
after the insult or 24 h later, they were subjected to antibody
treatment. Statistical analyses were performed with the Mann-Whitney
non-parametric test. **, p < 0.025; +,
p < 0.05; ++, p < 0.025 versus axotomized retinas.
|
|
 |
DISCUSSION |
Our study shows that a peak of induction of semaphorin expression
in the RGC and in the inner plexiform layer at the early stages
following complete axotomy of the optic nerve. This up-regulation was
detected in the RGC and in the inner plexiform layer of the axotomized
eyes and preceded the actual death process of the ganglion cells, which
is the inevitable outcome of such optic nerve injury in mammalians.
Moreover, we have shown that, by neutralizing semaphorin repulsive
activity using a single intravitreous injection of function-blocking anti-Sema3A antibodies, we could prolong the survival of RGC and obtain
dramatic protection from axotomy-induced degeneration. These results
are consistent with our previous in vitro experiments on
cultured neuronal cells exposed to an apoptosis-inducing challenge (22). In these studies, we have shown that a peak of induction of Sema3A expression occurred just prior to the commitment of sympathetic neurons to apoptosis, and prevention of cell death was
achieved using the same anti-Sema3A antibodies (22). Although the
in vitro experimental system utilized peripheral neuronal cells harvested from post-mitotic chick embryos, and the animal model
described in this study focused on central nervous system ganglion
cells from the rat retina, taken together, these data indicate the
existence of a common pathway. The correlation between the pivotal
roles played by semaphorins as mediators of neuronal fate in both the
in vitro and in vivo models suggests that
diffusible chemorepulsants may participate in a crucial step of
the apoptotic cascade. Indeed, a diffusible apoptosis-promoting
activity that is heat-labile was isolated from R28 retinal
cell-conditioned medium (56). The heat lability of the compound may
indicate that it is likely to be a secreted protein. This
apoptosis-inducing activity has not yet been characterized, but it is
supportive of our findings suggesting that semaphorins are candidates
for serving as diffusible apoptosis-promoting elements.
More importantly, we have shown that apoptosis can be blocked during
its early stages by antibodies that inhibit the axonal collapse
activity. Indeed, recent lines of evidence support the view that
repulsive cues are not restricted to the early stages of
neurodevelopment, but may also play a role in the response of axons to
their environment during adulthood. For instance, adult sensory neurons
were shown to retain the ability to respond to semaphorin III (57). In
addition, expression of semaphorin III was recently shown in selective
adult brain tissue (58). It is also likely that semaphorins are
involved in the pathogenesis of human neuronal degenerative diseases. A
further example of the role of semaphorins in pathological conditions
was reported by Fujita et al. (59). They found transient
up-regulation of neuropilin-1, neuropilin-2, and semaphorin 3A in rat
brain after occlusion of the cerebral artery distal to striate
branches. They suggest that neuropilin-1, neuropilin-2, and semaphorin
3A are involved in microglial/neuron interactions to phagocytose the dying neurons. Increased levels of CRMP-62, a protein involved in the
intracellular response to Sema3A, are associated with the pathological
process of neurofibrillary tangle formation in Alzheimer's disease
brains (60). Another study described an altered expression pattern of
semaphorin IV in Alzheimer's disease brains (61). Although semaphorin
IV expression does not co-localize with CRMP-2 expression in
Alzheimer's disease brains (61), these findings may still link its
accumulation with some of the pathological changes accompanying nerve
degeneration. The emerging concept therefore suggests that, as a result
of injury, neurons may react by up-regulation of proteins with a
repulsive signal.
Furthermore, we have shown that, by applying the function-blocking
anti-Sema3A antibodies to rats following optic nerve injury, we were
able to protect the RGC. Several possible explanations can be suggested
for the inhibitory mechanism displayed by neutralizing repulsive
signals. The first is based on the apoptosis-inducing capability of
semaphorins. When adult neurons are exposed to unscheduled high levels
of semaphorins, death signals are conveyed to the cell bodies, leading
to neuronal apoptosis (22, 25). Evidently, neutralizing the activity of
these proteins can prevent their toxic effects. A second possible
explanation is that the increase in repulsive signals can contribute to
unfavorable conditions leading to the failure of regenerative
processes, thus culminating in neuronal cell death. Indeed, decreased
Sema3A mRNA expression was recently reported as a temporary event
accompanying peripheral nerve crush (62). This down-regulation
was interpreted as an important mechanism enabling regenerative
attempts that occur after nerve injury (62). In accordance with this
concept, a transient up-regulation of semaphorin III mRNA was
indicated at the lesion site following axotomy of olfactory axons and
in neural scar tissue after injury to the adult central nervous system
(62, 63). It was even speculated that, by inhibiting the activity of
repulsive cues, promotion of regeneration processes could take place
(62). A third possible explanation is that anti-Sema3A antibodies
interfere with some other regulatory step of axotomy-induced apoptosis
that is non-relevant to inhibition of repulsive signals. Obviously, more studies are needed to gain a better understanding of
the molecular events that underlie the rescue of RGC from
axotomy-induced death. It is still unresolved whether neuropilin-1, the
downstream receptor of semaphorin III (23, 24), is involved in
conveying the repulsive cue into a death signal in axotomized RGC.
Although neuropilin-1 is known to be down-regulated in adult rat RGC
(64), it appears from our study that the RGC retain their
responsiveness to chemorepulsive signals following optic nerve injury.
Further support for a possible involvement of neuropilin-1 in this
process comes from our studies in cultured neuronal cells, in which
function-blocking anti-neuropilin-1 antibodies were able to inhibit the
death process (22).
The induction of semaphorins in the rat retina occurred during the
early stages of the time window that separates the retrograde death of
the RGC from the onset of the injury (i.e. axotomy). We have
taken advantage of this time lag and of the temporal up-regulation of
semaphorin expression to treat the damaged eye with a neuroprotective antibody. The delayed administration of the antibody did not impair its
neuroprotective ability, suggesting that a high percentage of the
neurons are still in the reversible stage and that it is therefore
still possible to rescue RGC even 24 h after the injury and to
achieve a high survival rate. It may be speculated that, in the case of
optic nerve injury in humans, physicians will have a time window of at
least 24 h to evaluate the clinical situation prior to treating
the patients with neuroprotective treatment or anti-apoptotic drugs.
There are many eye conditions in which neuroprotective treatment can
rescue RGC until the primary cause of injury to the optic nerve and
retina can be abolished. Among them are acute increase in intraocular
pressure, sudden occlusion of the central retinal artery, ischemic
optic neuropathy, retinal vein occlusion, and others (Refs. 66-68; for
review, see Ref. 69). It is tempting to speculate that this
neuroprotective approach may be applied not only to the visual system,
but also to injuries to the nervous system function. Obviously, further
studies need to be employed to test this theory. Our successful results
obtained in this study raise the possibility that blockage of axon
guidance molecules with chemorepulsive activity can serve (either alone or in combination with other neuroprotective agents) as an important novel strategy for modulation of neurodegeneration and of traumatic injury in the central nervous system.
It is of interest that the kinetics of semaphorin induction following
optic nerve axotomy are similar to those of c-Jun after optic
nerve crush (30). Both are rapidly up-regulated during the early days
post-injury; they reach a maximum of labeling intensity after 3 days
and then decline. Therefore, the list of immediate-early genes whose
expression is up-regulated in response to apoptotic triggers may also
be extended to include the semaphorins, which can be used as early
predictors of retinal degeneration.
In summary, we have described a model in which RGC survival in the
retina following optic nerve injury was enhanced by inhibiting repulsive cues. Our results suggest that diffusible chemorepulsive signals may have a direct effect on the survival of injured neurons and
that a therapeutic benefit can be obtained by inhibiting their function. In our experiments, we did not include functional studies of
the surviving neurons, and further studies of their ability to receive
and integrate synaptic inputs are still needed. In addition, future
studies should also examine whether longer-term survival can be
obtained using this strategy.
 |
ACKNOWLEDGEMENT |
We thank Prof. M. Schwartz for useful discussion.
 |
FOOTNOTES |
*
This work was supported in part by the National Parkinson
Foundation, by the Claire and Amedee Martier Institute for the Study of
Visual Disorders and Blindness, Tel Aviv University, and by the Israeli
Ministry of Health (to A. B.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence may be addressed: NST Ltd., 5 Odem St.,
Petach Tiqva, 49170 Israel. Tel.: 972-3-921-5717; Fax: 972-3-922-7581; E-mail: anat@nst.co.il.

To whom correspondence may be addressed. Tel.: 972-3-640-9782;
Fax: 972-3-640-7643; E-mail: barzilai@post.tau.ac.il.
Published, JBC Papers in Press, October 9, 2002, DOI 10.1074/jbc.M204793200
 |
ABBREVIATIONS |
The abbreviations used are:
Sema3A, semaphorin
3A;
RGC, retinal ganglion cell(s);
4-Di-10-Asp, 4-(4-(didecylamino)styryl)-N-methylpyridinium iodide;
PBS, phosphate-buffered saline;
KLH, keyhole limpet hemocyanin.
 |
REFERENCES |
| 1.
|
Nieto, M. A.
(1996)
Neuron
17,
1039-1048[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Tessier-Lavigne, M.,
and Goodman, C. S.
(1996)
Science
274,
1123-1131[Abstract/Free Full Text]
|
| 3.
|
Van Vactor, D. V.,
and Lorenz, L. J.
(1999)
Curr. Biol.
9,
R201-R204[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Varela-Echevarria, A.,
Tucker, A.,
Puschel, A. W.,
and Guthrie, S.
(1997)
Neuron
18,
193-207[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Kolodkin, A. L.
(1998)
Prog. Brain Res.
117,
115-132[Medline]
[Order article via Infotrieve]
|
| 6.
|
Mark, M. D.,
Lohrum, M.,
and Puschel, A. W.
(1997)
Cell Tissue Res.
290,
299-306[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Puschel, A. W.,
Adams, R. H.,
and Betz, H.
(1996)
Mol. Cell. Neurosci.
7,
419-431[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Yu, H. H.,
and Kolodkin, A. L.
(1999)
Neuron
22,
11-14[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Fan, J.,
Mansfield, G.,
Redmond, T.,
Gordon-Weeks, P. R.,
and Raper, J. A.
(1993)
J. Cell Biol.
121,
867-878[Abstract/Free Full Text]
|
| 10.
|
Driessens, M. H., Hu, H.,
Nobes, C. D.,
Self, A.,
Jordens, I.,
Goodman, C. S.,
and Hall, A.
(2001)
Curr. Biol.
11,
339-344[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Chen, H.,
Chedotal, A., He, Z.,
Goodman, C. S.,
and Tessier-Lavigne, M.
(1997)
Neuron
19,
547-559[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Fujisawa, H.,
and Kisukawa, T.
(1998)
Curr. Opin. Neurobiol.
8,
587-592[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Goshima, Y.,
Nakamura, F.,
Strittmatter, P.,
and Strittmatter, S. M.
(1995)
Nature
376,
509-514[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Jin, Z.,
and Strittmatter, S. M.
(1997)
J. Neurosci.
17,
6256-6263[Abstract/Free Full Text]
|
| 15.
|
Bagnard, D.,
Lohrum, M.,
Uziel, D.,
Puschel, A. W.,
and Bolz, J.
(1998)
Development
125,
5043-5053[Abstract]
|
| 16.
|
Song, H.,
Ming, G., He, Z.,
Lehmann, M.,
Tessier-Lavigne, M.,
and Poo, M.
(1998)
Science
281,
1515-1518[Abstract/Free Full Text]
|
| 17.
|
Behar, O.,
Golden, J. A.,
Mashimo, H.,
Schoen, F. J.,
and Fishman, M. C.
(1996)
Nature
383,
525-528[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Delaire, S.,
Elhabazi, A.,
Bensussan, A.,
and Boumsell, L.
(1998)
Cell. Mol. Life Sci.
54,
1265-1276[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Xu, X., Ng, S., Wu, Z. L. I.,
Nguyen, D.,
Homburger, S.,
Siedel-Dugan, C.,
Ebens, A.,
and Luo, Y.
(1998)
J. Biol. Chem.
273,
22428-22434[Abstract/Free Full Text]
|
| 20.
|
Sekido, Y.,
Bader, S.,
Latif, F.,
Chen, J. Y.,
Duh, F. M.,
Wei, M. H.,
Albanesi, J. P.,
Lee, C. C.,
Lerman, M. I.,
and Minna, J. D.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
4120-4125[Abstract/Free Full Text]
|
| 21.
|
Yamada, T.,
Endo, R.,
Gotoh, M.,
and Hirohashi, S.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
14713-14718[Abstract/Free Full Text]
|
| 22.
|
Shirvan, A.,
Ziv, I.,
Fleminger, G.,
Shina, R., He, Z.,
Brudo, I.,
Melamed, E.,
and Barzilai, A.
(1999)
J. Neurochem.
73,
961-971[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
He, Z.,
and Tessier-Lavigne, M.
(1997)
Cell
90,
739-751[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Kolodkin, A. L.,
Levengood, D. V.,
Rowe, E. G.,
Tai, Y.,
Giger, R. J.,
and Ginty, D. D.
(1997)
Cell
90,
753-762[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Gagliardini, V.,
and Fankhauser, C.
(1999)
Neuroscience
14,
301-316
|
| 26.
|
Bagnard, D.,
Vaillant, C.,
Khunth, S.-T.,
Dufay, N.,
Lohrum, M.,
Puschel, A. W.,
Belin, M.-F.,
and Thomasset, N.
(2001)
J. Neurosci.
21,
3332-3341[Abstract/Free Full Text]
|
| 27.
|
Berkelaar, M.,
Clarke, D. B.,
Wang, Y. C.,
Bray, G. M.,
and Aguayo, A. J.
(1994)
J. Neurosci.
14,
4368-4374[Abstract]
|
| 28.
|
So, K. F.,
and Yip, H. K.
(1998)
Vision Res.
38,
1525-1535[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Garcia-Valenzuela, E.,
Shareef, S.,
Walsh, J.,
and Sharma, S. C.
(1994)
Exp. Eye Res.
61,
33-44
|
| 30.
|
Isenmann, S.,
and Bahr, M.
(1997)
Exp. Neurol.
147,
28-36[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Rabacchi, S. A.,
Bonfanti, L.,
Liu, X. H.,
and Maffei, L.
(1994)
J. Neurosci.
14,
5292-5301[Abstract]
|
| 32.
|
Lieberman, A. R.
(1974)
in
Essays of the Nervous System
(Bellairs, G.
, and Gray, E. G., eds)
, pp. 71-105, Clarendon Press, Oxford
|
| 33.
|
Peinaldo-Ramon, P.,
Salvador, M.,
Villegas-Perez, M. P.,
and Vidal-Sanz, M.
(1996)
Investig. Ophthalmol. Vis. Sci.
37,
489-500[Abstract/Free Full Text]
|
| 34.
|
Villegas-Perez, M. P.,
Vidal-Sanz, M.,
Bray, G. M.,
and Aguayo, A. J.
(1998)
J. Neurosci.
8,
265-280[Abstract]
|
| 35.
|
Isenmann, S.,
Engel, S.,
Gillardon, F.,
and Bahr, M.
(1999)
Cell Death & Differ.
6,
673-682[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Thanos, S.,
Mey, J.,
and Wild, M.
(1993)
J. Neurosci.
13,
455-466[Abstract]
|
| 37.
|
Thanos, S.,
and Mey, J.
(1995)
J. Neurosci.
15,
1057-1079[Abstract]
|
| 38.
|
Koeberle, P. D.,
and Ball, A. K.
(1998)
Vision Res.
38,
1505-1515[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Isenmann, S.,
Klocker, N.,
Gravel, C.,
and Bahr, M.
(1998)
Eur. J. Neurosci.
10,
2751-2756[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Kermer, P.,
Klocker, N.,
Labes, M.,
and Bahr, M.
(1998)
J. Neurosci.
18,
4656-4662[Abstract/Free Full Text]
|
| 41.
|
Lucius, R.,
and Sievers, J.
(1997)
Brain Res. Mol. Brain Res.
48,
181-184[Medline]
[Order article via Infotrieve]
|
| 42.
|
Lazarov-Spiegler, O.,
Solomon, A. S.,
and Schwartz, M.
(1999)
Vision Res.
39,
169-175[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Bonfanti, L.,
Strettoi, E.,
Chierzi, S.,
Cenni, M. C.,
Liu, Z. H.,
Martinou, J. C.,
Maffei, L.,
and Rabacchi, S. A.
(1996)
J. Neurosci.
16,
4186-4194[Abstract/Free Full Text]
|
| 44.
|
Chierzi, S.,
Cenni, M. C.,
Maffei, L.,
Pizzorusso, T.,
Porciatti, V.,
Ratto, G. M.,
and Strettoi, E.
(1998)
Vision Res.
38,
1537-1543[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Solomon, A. S.,
Lavie, V.,
Hauben, U.,
Monsonego, A.,
Yoles, E.,
and Schwartz, M.
(1996)
J. Neurosci. Methods
70,
21-25[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Luo, Y.,
Raible, D.,
and Raper, J. A.
(1993)
Cell
75,
217-227[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Bursch, W.,
Kleine, L.,
and Tenniswood, M.
(1990)
Biochem. Cell Biol.
68,
1071-1074[Medline]
[Order article via Infotrieve]
|
| 48.
|
Shirvan, A.,
Shina, R.,
Ziv, I.,
Melamed, E.,
and Barzilai, A.
(2000)
Mol. Brain Res.
83,
81-93[Medline]
[Order article via Infotrieve]
|
| 49.
|
Mey, J.,
and Thanos, S.
(1993)
Brain Res.
602,
304-317[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Adamus, G.,
Machnicki, M.,
Elerding, H.,
Sugden, B.,
Blocker, Y. S.,
and Fox, D. A.
(1998)
J. Autoimmun.
11,
523-533[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Djamgoz, M. B.,
Evans-Capp, A. J.,
and Wagner, H. J.
(1996)
J. Neurosci. Methods
64,
237-243[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Lambiase, A.,
Centofanti, M.,
Micera, A.,
Manni, G. L.,
Mattei, E.,
De Gregorio, A.,
de Feo, G.,
Bucci, M. G.,
and Aloe, L.
(1997)
Graefes's Arch. Clin. Exp. Ophthalmol.
235,
780-785
|
| 53.
|
Mordenti, J.,
Thomsen, K.,
Licko, V.,
Berleau, L.,
Kahn, J. W.,
Cuthbertson, R. A.,
Duenas, E. T.,
Ryan, A. M.,
Schofield, C.,
Berger, T. W.,
Meng, Y. G.,
and Cleland, J.
(1999)
Toxicol. Sci.
52,
101-106[Abstract/Free Full Text]
|
| 54.
|
Ohguro, H.,
Ogawa, K.,
Maeda, T.,
Maeda, A.,
and Maruyama, I.
(1999)
Investig. Ophthalmol. Vis. Sci.
40,
3160-3167[Abstract/Free Full Text]
|
| 55.
|
Verma, M. J.,
Mukaida, N.,
Vollmer-Conna, U.,
Matsushima, K.,
Lloyd, A.,
and Wakefield, D.
(1999)
Investig. Ophthalmol. Vis. Sci.
40,
2465-2470[Abstract/Free Full Text]
|
| 56.
|
Seigel, G. M.,
and Liu, L.
(1997)
Mol. Vis.
3,
14-18[Medline]
[Order article via Infotrieve]
|
| 57.
|
Tanelian, D. L.,
Barry, M. A.,
Johnston, S. A.,
and Smith, G. M.
(1997)
Nat. Med.
3,
1398-1401[CrossRef][Medline]
[Order article via Infotrieve]
|
| 58.
|
Giger, R. J.,
Pasterkamp, R. J.,
Heijnen, S.,
Holtmaat, A. J.,
and Verhaagen, J.
(1998)
J. Neurosci. Res.
52,
27-42[CrossRef][Medline]
[Order article via Infotrieve]
|
| 59.
|
Fujita, H.,
Zhang, B.,
Sato, K.,
Tanka, J.,
and Sakanaka, M.
(2001)
Brain Res.
914,
1-14[CrossRef][Medline]
[Order article via Infotrieve]
|
| 60.
|
Yoshida, H.
(1998)
J. Biol. Chem.
273,
9761-9768[Abstract/Free Full Text]
|
| 61.
|
Hirsch, E., Hu, L. J.,
Prigent, A.,
Constantin, B.,
Agid, Y.,
Drabkin, H.,
and Roche, J.
(1999)
Brain Res.
823,
67-79[CrossRef][Medline]
[Order article via Infotrieve]
|
| 62.
|
Pasterkamp, R. J.,
Giger, R.,
and Verhaagen, J.
(1998)
Exp. Neurol.
153,
313-327[CrossRef][Medline]
[Order article via Infotrieve]
|
| 63.
|
Pasterkamp, R. J.,
Giger, R. J.,
Ruitenberg, M. J.,
Holtmaat, A. J., De,
Wit, J., De,
Winter, F.,
and Verhaagen, J.
(1999)
Mol. Cell. Neurosci.
13,
143-166[CrossRef][Medline]
[Order article via Infotrieve]
|
| 64.
|
Kawakami, A.,
Kitsukawa, T.,
Takagi, S.,
and Fujisawa, H.
(1996)
J. Neurobiol.
29,
1-17[CrossRef][Medline]
[Order article via Infotrieve]
|
| 65.
|
Harlow, E.,
and Lane, D.
(1988)
A Laboratory Manual
, pp. 490-492, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 66.
|
Lafuente, M. P.,
Villegas-Perez, M. P.,
Sobrado-Calvo, P.,
Garcia-Aviles, A.,
Miralles de Imperial, J.,
and Vidal-Sanz, M.
(2001)
Investig. Ophthalmol. Vis. Sci.
42,
2074-2084[Abstract/Free Full Text]
|
| 67.
|
Cuevas, P.,
Carceller, F.,
Redondo-Horcajo, M.,
Lozano, R. M.,
and Gimenez-Gallego, G.
(1998)
Neurosci. Lett.
255,
1-4[CrossRef][Medline]
[Order article via Infotrieve]
|
| 68.
|
Levin, L. A.
(1999)
Surv. Ophthalmol.
43,
S98-S101
|
| 69.
|
Schwartz, M.,
Belkin, M.,
Yoles, E.,
and Solomon, A. S.
(1996)
J. Glaucoma
5,
427-432[Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Moretti, A. Procopio, R. Lazzarini, M. R. Rippo, R. Testa, M. Marra, L. Tamagnone, and A. Catalano
Semaphorin3A signaling controls Fas (CD95)-mediated apoptosis by promoting Fas translocation into lipid rafts
Blood,
February 15, 2008;
111(4):
2290 - 2299.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. X. Jiang, M. Sheldrick, A. Desbois, J. Slinn, and S. T. Hou
Neuropilin-1 Is a Direct Target of the Transcription Factor E2F1 during Cerebral Ischemia-Induced Neuronal Death In Vivo
Mol. Cell. Biol.,
March 1, 2007;
27(5):
1696 - 1705.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. H. Majed, S. Chandran, S. P. Niclou, R. S. Nicholas, A. Wilkins, M. G. Wing, K. E. Rhodes, M. G. Spillantini, and A. Compston
A Novel Role for Sema3A in Neuroprotection from Injury Mediated by Activated Microglia
J. Neurosci.,
February 8, 2006;
26(6):
1730 - 1738.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Uchida, T. Ohshima, Y. Sasaki, H. Suzuki, S. Yanai, N. Yamashita, F. Nakamura, K. Takei, Y. Ihara, K. Mikoshiba, et al.
Semaphorin3A signalling is mediated via sequential Cdk5 and GSK3{beta} phosphorylation of CRMP2: implication of common phosphorylating mechanism underlying axon guidance and Alzheimer's disease
Genes Cells,
February 1, 2005;
10(2):
165 - 179.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. de Winter, Q. Cui, N. Symons, J. Verhaagen, and A. R. Harvey
Expression of Class-3 Semaphorins and Their Receptors in the Neonatal and Adult Rat Retina
Invest. Ophthalmol. Vis. Sci.,
December 1, 2004;
45(12):
4554 - 4562.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Goldberg, M. E. Vargas, J. T. Wang, W. Mandemakers, S. F. Oster, D. W. Sretavan, and B. A. Barres
An Oligodendrocyte Lineage-Specific Semaphorin, Sema5A, Inhibits Axon Growth by Retinal Ganglion Cells
J. Neurosci.,
May 26, 2004;
24(21):
4989 - 4999.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Kikuchi, A. Kishino, O. Konishi, K. Kumagai, N. Hosotani, I. Saji, C. Nakayama, and T. Kimura
In Vitro and in Vivo Characterization of a Novel Semaphorin 3A Inhibitor, SM-216289 or Xanthofulvin
J. Biol. Chem.,
October 31, 2003;
278(44):
42985 - 42991.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. I. Dubreuil, M. J. Winton, and L. McKerracher
Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system
J. Cell Biol.,
July 21, 2003;
162(2):
233 - 243.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|